Stefan Schwartz

16PUBLICATIONS
96CO-AUTHORS
Gene and molecular therapyHaematological tumoursEpidemiological methodsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Mar 13, 2026
IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Johanna M Horns, Thomas Beder, Axel Künstner

|Jan 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Oct 20, 2025
Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.

M Korenkov, J Liebaert, S Yousefian

|Mar 25, 2025
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.

Michaela Kotrová, Constantin Proske, Nikos Darzentas

|Mar 13, 2025
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid.

Jesper Heldrup, Archie Bleyer, Laura Ramsey

Pageof 3

Frequent Collaborators

4 joint publications

Etienne Chatelut

4 joint publications

Carmelo Rizzari

4 joint publications

Scott Howard

4 joint publications

Miriam Hwang